Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09QWD
|
|||
| Former ID |
DIB002291
|
|||
| Drug Name |
CEP-37251
|
|||
| Synonyms |
ART-010; EGX-010; OVP (bone loss), Peptech; Osteoprotegerin variant protein (bone loss), Arana; Osteoprotegerin variant protein (bone loss), EvoGenix; Osteoprotegerin variant protein (bone loss), Peptech
Click to Show/Hide
|
|||
| Indication | Bone metastases [ICD-11: 2D50; ICD-10: C79.5; ICD-9: 198.5] | Phase 1 | [1] | |
| Company |
EvoGenix Pty Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Osteoclast differentiation factor (ODF) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Osteoclast differentiation | ||||
| Prolactin signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TWEAK Signaling Pathway | ||||
| Pathway Interaction Database | IL6-mediated signaling events | |||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNFs bind their physiological receptors | ||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | Osteoblast Signaling | |||
| Vitamin D Receptor Pathway | ||||
| Differentiation Pathway | ||||
| RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01159873) Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women. U.S. National Institutes of Health. | |||
| REF 2 | This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.